PDF(Pubmed)
Abstract：
UNASSIGNED: The current prophylactic tuberculosis vaccine Bacille Calmette-Guérin (BCG), was derived in the 1920s, but the humoral immune responses induced by BCG vaccination have not been fully elucidated to date. In this study, our aim was to reveal the profiles of antibody responses induced by BCG vaccination in adults and identify the potential biomarkers for evaluating the BCG vaccination response.
UNASSIGNED: Proteome microarrays were performed to reveal the serum profiles of antibody responses induced by BCG vaccination in adults. ELISA was used to validate the potential biomarkers in validation cohort (79 healthy controls and 58 BCG-vaccinated subjects). Then combined panel was established by logistic regression analysis based on OD values of potential biomarkers.
UNASSIGNED: Multiple antigens elicited stronger serum IgG or IgM antibody responses in BCG vaccinated subjects than healthy subjects at 12 weeks post BCG vaccination; among the antigens, Rv0060, Rv2026c and Rv3379c were further verified using 137 serum samples and presented the moderate performance in assessment of the BCG vaccination response by receiver operating characteristic analysis. Furthermore, a combined panel exhibited an improved AUC of 0.923, and the sensitivity and specificity were 77.59 % and 91.14 %, respectively. In addition, the antibody response against Rv0060, Rv2026c and Rv3379c was related to the clinical background to a certain extent.
UNASSIGNED: The novel antigens identified in our study could offer better knowledge towards developing a more efficacious vaccine based on humoral immune responses, and they could be potential biomarkers in assessments of BCG vaccination responses.
UNASSIGNED: Proteome microarrays were performed to reveal the serum profiles of antibody responses induced by BCG vaccination in adults. ELISA was used to validate the potential biomarkers in validation cohort (79 healthy controls and 58 BCG-vaccinated subjects). Then combined panel was established by logistic regression analysis based on OD values of potential biomarkers.
UNASSIGNED: Multiple antigens elicited stronger serum IgG or IgM antibody responses in BCG vaccinated subjects than healthy subjects at 12 weeks post BCG vaccination; among the antigens, Rv0060, Rv2026c and Rv3379c were further verified using 137 serum samples and presented the moderate performance in assessment of the BCG vaccination response by receiver operating characteristic analysis. Furthermore, a combined panel exhibited an improved AUC of 0.923, and the sensitivity and specificity were 77.59 % and 91.14 %, respectively. In addition, the antibody response against Rv0060, Rv2026c and Rv3379c was related to the clinical background to a certain extent.
UNASSIGNED: The novel antigens identified in our study could offer better knowledge towards developing a more efficacious vaccine based on humoral immune responses, and they could be potential biomarkers in assessments of BCG vaccination responses.
摘要：
■目前的预防性结核病疫苗BacilleCalmette-Guérin（BCG），起源于1920年代，但迄今为止，BCG疫苗诱导的体液免疫反应尚未完全阐明。在这项研究中,我们的目的是揭示成人BCG疫苗诱导的抗体应答谱,并确定潜在的生物标志物,用于评估BCG疫苗应答.
■进行蛋白质组微阵列以揭示成人中由BCG疫苗接种诱导的抗体应答的血清谱。ELISA用于验证验证队列(79名健康对照和58名接种BCG的受试者)中的潜在生物标志物。然后基于潜在生物标志物的OD值通过逻辑回归分析建立组合面板。
■在接种卡介苗后12周时，与健康受试者相比，多种抗原在接种卡介苗的受试者中引起更强的血清IgG或IgM抗体应答；在抗原中，使用137份血清样品进一步验证了Rv0060、Rv2026c和Rv3379c，并通过接受者操作特性分析在评估BCG疫苗接种反应方面表现中等。此外，组合面板表现出0.923的AUC改善，灵敏度和特异性分别为77.59%和91.14%，分别。此外,Rv0060、Rv2026c和Rv3379c的抗体应答在一定程度上与临床背景有关。
■在我们的研究中确定的新抗原可以为开发基于体液免疫反应的更有效的疫苗提供更好的知识，它们可能是评估BCG疫苗接种反应的潜在生物标志物。
■进行蛋白质组微阵列以揭示成人中由BCG疫苗接种诱导的抗体应答的血清谱。ELISA用于验证验证队列(79名健康对照和58名接种BCG的受试者)中的潜在生物标志物。然后基于潜在生物标志物的OD值通过逻辑回归分析建立组合面板。
■在接种卡介苗后12周时，与健康受试者相比，多种抗原在接种卡介苗的受试者中引起更强的血清IgG或IgM抗体应答；在抗原中，使用137份血清样品进一步验证了Rv0060、Rv2026c和Rv3379c，并通过接受者操作特性分析在评估BCG疫苗接种反应方面表现中等。此外，组合面板表现出0.923的AUC改善，灵敏度和特异性分别为77.59%和91.14%，分别。此外,Rv0060、Rv2026c和Rv3379c的抗体应答在一定程度上与临床背景有关。
■在我们的研究中确定的新抗原可以为开发基于体液免疫反应的更有效的疫苗提供更好的知识，它们可能是评估BCG疫苗接种反应的潜在生物标志物。
